Eli Lilly and Co. (LLY) announced Friday the presentation of post-hoc analyses showing improvements in daily functioning and reductions in disability in patients with chronic and episodic migraine treated with Emgality (galcanezumab-gnlm) compared to placebo.
from RTT - Biotech https://ift.tt/2LLDgn3
via IFTTT
No comments:
Post a Comment